Allegheny Health Network

America is in the midst of a behavioral health (BH) crisis. Incidence of most BH conditions is increasing and affecting all age groups, from children to older adults. In parallel, many counties in the United States lack an adequate supply of BH providers, and staffing shortages are exacerbated by a high rate of burnout and a low-efficacy case assignment model that does not thoughtfully match a patient and a provider. When access does exist, it often is not timely, with wait times up to 6 months. This crisis has been dramatically worsened by the coronavirus disease 2019 pandemic. Based on these challenges, Highmark Health, a national blended health organization that offers a diverse portfolio of health insurance, health care delivery, and related solutions, developed a mental well-being program via collaboration and partnership with Spring Health, a company that offers a comprehensive mental health system developed to address the needs of employers and health plans. Highmark Health's goals for this collaboration include (1) improving the quality and clinical outcomes of BH for Highmark members, (2) expanding access to BH care and interventions for members, (3) creating a BH system that uses data to inform operations and clinical decisions, (4) tracking key outcomes measures to assess program impact, and (5) reducing stigma associated with BH conditions and help-seeking. A phased rollout of the Mental Well-Being (MWB) program began in January 2024. The effort involved technical integration among the parties to place the MWB solution in health plan member portals. Using a structured intake process that includes a detailed self-assessment, personalized care plans were developed across a spectrum of levels of support. Interventions span a range of digital daily wellness interactions, such as one-on-one care navigation, or more in-depth behavioral care provided virtually or with in-person provider visits. Care plans include the use of routine, clinically validated self-assessments that are used to monitor and guide care. Behavioral therapy, medication management, and 24/7 crisis support are offered. Initial findings of this MWB program show an average wait time in 2025 of less than 2 days. Among members diagnosed with moderate-to-severe depression and anxiety who are receiving care in this MWB program, in 2024, remission was achieved in about four and five appointments, respectively. Of about 51,000 MWB-enrolled members in 2024, about 78.5% of participants are engaging with BH services for the first time.

Long-context audio reasoning is underserved in both training data and evaluation. Existing benchmarks target short-context tasks, and the open-ended generation tasks most relevant to long-context reasoning pose well-known challenges for automatic evaluation. We propose a synthetic data generation pipeline designed to serve both as a training resource and as a controlled evaluation environment, and instantiate it for first-visit doctor-patient conversations with SOAP note generation as the task. The pipeline has three stages, persona-driven dialogue generation, multi-speaker audio synthesis with overlap/pause modeling, room acoustics, and sound events, and LLM-based reference SOAP note production, built entirely on open-weight models. We release 8,800 synthetic conversations with 1.3k hours of corresponding audio and reference notes. Evaluating current open-weight systems, we find that cascaded approaches still substantially outperform end-to-end models.

OBJECTIVE:Using a hydroxychloroquine (HCQ) dose of 5 mg/kg/day in systemic lupus erythematosus (SLE) is associated with a higher risk of flares; HCQ blood level monitoring could be a better way to adjust the HCQ dose. We studied the upper threshold for a reference range of HCQ levels to inform routine monitoring. METHODS:This observational study included patients (N = 2,010) across the Systemic Lupus International Collaborating Clinics, Wisconsin, international, and French studies who underwent HCQ blood level measurements. Using adjusted spline and logistic regression analyses on the cross-sectional data, we first identified an HCQ blood level associated with higher HCQ toxicity. Next, we tested if this upper threshold level was supratherapeutic (no further risk reduction for the Systemic Lupus Erythematosus Disease Activity Index 2000 [score ≥6]). Finally, we examined associations between chronic kidney disease (CKD) stage and supratherapeutic (toxic) HCQ blood levels. RESULTS:Among 1,842 patients (excluding 168 patients with very low HCQ blood levels), 4.9% had HCQ-related toxicity. Odds of toxicity were 2.1-fold higher with blood levels ≥1,150 ng/mL and 1.7-fold higher with the cumulative HCQ dose per 1,000-g increase. Blood levels ≥1,150 ng/mL were associated with a saturation in therapeutic effect, indicating supratherapeutic levels. Patients with CKD stage ≥3 had 2.3-fold higher odds of having supratherapeutic levels (≥1,150 ng/mL). CONCLUSION:The therapeutic reference range for HCQ blood level monitoring is 750 to <1,150 ng/mL. HCQ level monitoring could optimize HCQ use, particularly in patients with CKD stage ≥3. Future longitudinal studies are needed to validate the use of HCQ blood level monitoring in optimizing dosing.

BACKGROUND:Endovascular thrombectomy (EVT) has transformed acute ischemic stroke (AIS) care, with onset-to-puncture (OTP) time widely recognized as a critical determinant of outcome. However, emerging evidence suggests that in-hospital procedure time (PT)-from arterial puncture to final recanalization-may have an equally or more significant impact. This study examines the relative contribution of PT versus OTP to functional outcomes in patients with AIS undergoing EVT. METHODS:A retrospective analysis was conducted of 6644 patients with AIS treated at 44 international stroke centers from the Stroke Thrombectomy and Aneurysm Registry (STAR; 2016-2023). Multivariable regression, time-equivalence analysis, and marginal effects modeling were used to assess associations between PT, OTP, and 90-day modified Rankin Scale (mRS) outcomes. Centers were stratified by procedural efficiency and compared using propensity score matching (PSM). Mediation analysis evaluated whether PT accounted for inter-center differences. RESULTS:PT and OTP were independently associated with functional outcomes; however, PT had a significantly stronger effect (adjusted OR for mRS 0-2: PT=0.56 vs OTP=0.96 per hour). Each 5 min increase in PT was equivalent to 78-100 min of additional OTP in outcome impact. Centers with faster average PT had higher rates of functional independence (number needed to treat (NNT)=10), fewer complications, and lower symptomatic intracranial hemorrhage rates. PT significantly mediated the relationship between center tier and outcomes (Sobel's P<0.001). CONCLUSION:While minimizing OTP remains important, PT exerts a greater influence on outcomes after EVT. Procedural efficiency should be emphasized in stroke systems of care and included in center performance metrics to improve patient outcomes.

PURPOSE:Relapse is a major cause of failure in human papillomavirus-independent head and neck squamous cell carcinoma. Clinicopathologic criteria for adjuvant treatment remain imprecise and have not changed for decades. We investigated whether ctDNA in lymphatic exudate collected via surgical drains ("lymph") 24 hours after surgery identified molecular residual disease (MRD) and compared its performance with time-matched plasma. EXPERIMENTAL DESIGN:Using an ultra-sensitive tumor-informed sequencing approach, tumor variants were called in lymph and plasma to classify patients as ctDNA positive or ctDNA negative, trained in an initial cohort of 36 patients, and replicated in an independent cohort of 37 patients. Progression-free survival was compared in ctDNA(+) versus ctDNA(-) patients. RESULTS:Lymph identified MRD in two independent multi-site cohorts (initial cohort sensitivity = 76% and specificity = 63%; log-rank P = 0.01; replication cohort sensitivity = 65% and specificity = 70%; log-rank P = 0.04). Lymph performance was enhanced in locoregional relapse (sensitivity = 78% and specificity = 67%; log-rank P = 0.0004) and generalized to early-stage patients. Analysis of matched plasma collected at this early timepoint was not predictive of recurrence (sensitivity = 35% and specificity = 72%; log-rank P = 0.7). In patients with intermediate-risk pathology, lymph ctDNA was associated with recurrence (sensitivity = 88% and specificity = 67%; log-rank P = 0.0008), suggesting an opportunity for improved stratification of patients who may benefit from additional adjuvant treatment. CONCLUSIONS:Postoperative lymph is a novel, proximal, and early source of MRD with the potential to introduce more precision into adjuvant therapy decision-making and improve outcomes, especially for patients with intermediate-risk human papillomavirus-independent head and neck squamous cell carcinoma.